Compare · CUE vs NVO
CUE vs NVO
Side-by-side comparison of Cue Biopharma Inc. (CUE) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CUE and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 1108.4x CUE ($194.4M).
- Over the past year, CUE is up 7.2% and NVO is down 12.1% - CUE leads by 19.3 points.
- CUE has been more active in the news (12 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 5 for CUE).
- Company
- Cue Biopharma Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $194.4M
- $215.46B
- 1M return
- -17.07%
- -2.08%
- 1Y return
- +7.20%
- -12.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 12
- 9
- Recent ratings
- 5
- 25
Cue Biopharma Inc.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a fusion protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 would also leverage the IL-2 based CUE-100 framework and target an antigen to be selected in collaboration with LG Chem; CUE-200 framework that utilizes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences to the development of Immuno-STATs focused in the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CUE
- SEC Form EFFECT filed by Cue Biopharma Inc.
- Chief Legal Compliance Officer Ray Sumita converted options into 18,196 shares and sold $265,628 worth of shares (8,829 units at $30.09), increasing direct ownership by 9% to 118,545 units (SEC Form 4) to satisfy tax liability
- VP, Prin. Accounting Officer Meluzio Michael Vincent converted options into 13,647 shares and sold $169,324 worth of shares (5,628 units at $30.09), increasing direct ownership by 20% to 48,961 units (SEC Form 4) (tax liability)
- Chief Executive Officer Lin Shao-Lee converted options into 109,179 shares and sold $1,606,562 worth of shares (58,258 units at $27.58), increasing direct ownership by 8% to 705,995 units (SEC Form 4) to cover withholding tax
- Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- SEC Form SCHEDULE 13G filed by Cue Biopharma Inc.
- SEC Form 144 filed by Cue Biopharma Inc.
- SEC Form S-3 filed by Cue Biopharma Inc.
- SEC Form 8-K filed by Cue Biopharma Inc.
- Chief Financial Officer Ahlers James M was granted 25,500 shares (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S